Baseline characteristics and FUAS parameters of the 643 patients
enrolled in this study are summarized in Table 1. The median follow-up
time were 29 (2-62) months. 288 (55.2%) patients were included in FUAS
group, while 355 (44.8%) patients were included in FUAS+ (combined with
GnRH-a and/or mirena) group. The rates of endometriosis in FUAS group
(18.7%) was higher than that in FUAS+ group (12.7%) (P﹤0.05), whereas
there were no significant differences between two groups in terms of
baseline characteristics and FUAS parameters (P>0.05, Table S1).